Pear Therapeutics (PEAR) Misses Q3 EPS by 1c

Pear Therapeutics (NASDAQ: PEAR) reported Q3 EPS of ($0.22), $0.01 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4.34 million.

For earnings history and earnings-related data on Pear Therapeutics (PEAR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery